Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

Migration, Crosslink

📖

Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-section-147-neuroimmun

📖 Wiki Page

therapeutic1257 wordssynced 2026-04-02

Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

147.1 Rationale for Targeting Neuroimmune Communication

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2 agonist</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>TREM2 agonist</td>
</tr>
<tr>
<td class="label">DNL311</td>
<td>TREM2 bispecific</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3 inhibitor</td>
</tr>
<tr>
<td class="label">Colchicine</td>
<td>Microtubule inhibition</td>
</tr>
<tr>
<td class="label">MCC940</td>
<td>NLRP3 inhibitor</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">C1q</td>
<td>ANX005</td>
</tr>
<tr>
<td class="label">C3</td>
<td>Pegcetacoplan</td>
</tr>
<tr>
<td class="label">C1q</td>
<td>VIB7710</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">A1 phenotype blockade</td>
<td>LDN</td>
</tr>
<tr>
<td class="label">Reactive astrocyte modulation</td>
<td>Beta-lactam antibiotics</td>
</tr>
<tr>
<td class="label">Metabolic support</td>
<td>Alpha-lipoic acid</td>
</tr>
<tr>
<td class="label

...

Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

147.1 Rationale for Targeting Neuroimmune Communication

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2 agonist</td>
</tr>
<tr>
<td class="label">AL003</td>
<td>TREM2 agonist</td>
</tr>
<tr>
<td class="label">DNL311</td>
<td>TREM2 bispecific</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>NLRP3 inhibitor</td>
</tr>
<tr>
<td class="label">Colchicine</td>
<td>Microtubule inhibition</td>
</tr>
<tr>
<td class="label">MCC940</td>
<td>NLRP3 inhibitor</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">C1q</td>
<td>ANX005</td>
</tr>
<tr>
<td class="label">C3</td>
<td>Pegcetacoplan</td>
</tr>
<tr>
<td class="label">C1q</td>
<td>VIB7710</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">A1 phenotype blockade</td>
<td>LDN</td>
</tr>
<tr>
<td class="label">Reactive astrocyte modulation</td>
<td>Beta-lactam antibiotics</td>
</tr>
<tr>
<td class="label">Metabolic support</td>
<td>Alpha-lipoic acid</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Assessments</td>
</tr>
<tr>
<td class="label">Baseline</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">Week 8</td>
<td>Blood</td>
</tr>
<tr>
<td class="label">Week 16</td>
<td>CSF (optional), clinical</td>
</tr>
<tr>
<td class="label">Ongoing</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Levodopa Interaction</td>
</tr>
<tr>
<td class="label">LDN</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Dapansutrile</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Omega-3</td>
<td>May affect absorption; separate by 2h</td>
</tr>
<tr>
<td class="label">Colchicine</td>
<td>Avoid (levodopa interaction)</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanism validity</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Clinical readiness</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Safety profile</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Combination potential</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Biomarker availability</td>
<td>7/10</td>
</tr>
</table>

The neuroimmune interface represents the critical bidirectional communication network between neurons and immune cells—primarily microglia and astrocytes—in the central nervous system. In 4R-tauopathies like corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), this communication network becomes profoundly dysregulated, contributing to disease progression through chronic neuroinflammation, synaptic loss, and neuronal dysfunction[@mangold2021].

Pathological alterations in CBS/PSP:

Microglial activation: Prominent in affected brain regions (basal ganglia, brainstem, frontal cortex)
Astrocyte reactivity: Tufted astrocytes are a hallmark of PSP
Complement activation: C1q and C3 mediate excessive synaptic pruning
Cytokine elevation: TNF-α, IL-1β, IL-6 elevated in CSF
TREM2 dysfunction: Impaired phagocytic clearance of tau aggregates

Therapeutic modulation of neuroimmune communication offers a complementary approach to direct anti-tau therapies, potentially enhancing clearance mechanisms while reducing neurotoxic inflammation.

147.2 Glial-Neuronal Crosstalk Pathways

CX3CL1/CX3CR1 Signaling Axis

The fractalkine pathway provides the primary inhibitory communication channel from neurons to microglia:

Neuronal CX3CL1: Constitutively expressed, delivers anti-inflammatory signals
Microglial CX3CR1: Receptor that maintains quiescent state under physiological conditions
Therapeutic restoration: CX3CR1 agonists and CX3CL1 analogs being developed

Evidence in tauopathy:

CX3CL1 expression decreases with age and in PSP
CX3CR1 knockout mice show enhanced neuroinflammation
Overexpression protective in animal models[@griffiths2023]

CD200/CD200R Pathway

The CD200-CD200R axis provides another critical inhibitory signal:

Neuronal CD200: Membrane glycoprotein delivering inhibitory signals
Microglial CD200R: Contains ITIMs that recruit phosphatases
Therapeutic potential: CD200R agonists under exploration

Astrocyte-Neuron Metabolic Coupling

Astrocytes support neuronal function through:

Lactate shuttling to neurons
Potassium buffering
Glutamate uptake and recycling
Glycogen storage and release

Therapeutic enhancement:

Astrocyte metabolic support (lactate supplementation)
Glutamate transporter modulators
Potassium channel targeting

Astrocyte-Microglia Communication

Bidirectional signaling between astrocytes and microglia:

Mermaid diagram (expand to render)

147.3 Therapeutic Targets

TREM2 Modulation

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) bridges lipid sensing and microglial activation[@deczkowska2020]:

Rationale for CBS/PSP:

TREM2 recognizes lipid components of tau aggregates
Enhances phagocytosis of tau debris
Supports disease-associated microglia (DAM) phenotype

NLRP3 Inflammasome Inhibition

The NLRP3 inflammasome drives production of pro-inflammatory cytokines[@heneka2019]:

Evidence in tauopathy:

NLRP3 activated by tau aggregates
IL-1β drives tau phosphorylation
Inhibition reduces pathology in mouse models

Complement System Modulation

Complement C1q and C3 mediate pathological synaptic pruning:

Astrocyte-Targeted Therapies

147.4 Clinical Implementation Protocol

Patient Assessment

Biomarkers for patient stratification:

CSF YKL-40 (chitinase-3-like protein): Astrocyte activation
CSF sTREM2: Microglial activation
PET TSPO: Neuroinflammation burden
GFAP: Reactive astrocytes

Therapeutic Protocol

Phase 1: Baseline Assessment (Weeks 1-4)

Baseline biomarkers: YKL-40, sTREM2, GFAP, NfL

TSPO PET if available

Review current medications for interactions

Phase 2: Therapeutic Intervention (Weeks 5-16)

Option A: Near-term approach

Low-dose naltrexone (LDN): 1.5-4.5mg nightly
Mechanism: Glial modulation via opioid receptor antagonism
Evidence: Case reports in PSP
Cost: $$
Safety: Generally well-tolerated
Dapansutrile (if available):
Mechanism: NLRP3 inhibition
Dosing: 100-200mg BID
Evidence: Inflammatory conditions
Omega-3 fatty acids (2-3g EPA/DHA daily):
Mechanism: Anti-inflammatory, SPM production
Evidence: Modest benefit in neurodegenerative disease
Cost: $$

Phase 3: Disease-Modifying Approaches (Ongoing)

Monitor for TREM2 agonists entering CBS/PSP trials
Consider CSF1R inhibitor trials when available
Evaluate complement inhibitor programs

Monitoring Schedule

147.5 Drug Interactions with Current Regimen

147.6 NET Assessment

Total NET Assessment: 37/50 (74%)

147.7 Patient-Specific Recommendations

For this 50-year-old male CBS/PSP patient with DAT scan-confirmed tauopathy:

Start LDN: 1.5mg nightly, titrate to 4.5mg over 4 weeks

Omega-3 supplementation: 2g EPA+DHA daily

Monitor biomarkers: YKL-40, NfL at baseline and 16 weeks

Consider clinical trials: Watch for TREM2 agonist trials in tauopathy

Avoid: Colchicine (MAO-B contraindication)

Timeline:

Immediate: Start LDN + omega-3
3-6 months: Evaluate response, biomarker changes
6-12 months: Assess for trial eligibility

147.8 Cross-Links

[Neuroimmune Interface Pathway](/mechanisms/neuroimmune-interface)
[Neuroinflammation in PSP](/mechanisms/neuroinflammation-psp)
[TREM2 Therapeutics](/therapeutics/trem2-therapeutics)
[CSF1R Inhibitors](/therapeutics/csf1r-inhibitors-neurodegeneration)
[Microglia in Neurodegeneration](/cell-types/microglia)
[Astrocyte Reactivity](/mechanisms/astrocyte-reactivity)

147.9 References

[Mangold CA, Wold LE. The neuroimmune interface: cytokine networks in brain aging. Ageing Res Rev. 2021](https://pubmed.ncbi.nlm.nih.gov/33276197/)

[Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017](https://pubmed.ncbi.nlm.nih.gov/28636959/)

[Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020](https://pubmed.ncbi.nlm.nih.gov/32521223/)

[Heneka MT, McManus RM, Latz E. NLRP3 inflammasome in spatial and temporal memory. Nat Rev Neurosci. 2019](https://pubmed.ncbi.nlm.nih.gov/31363276/)

[Griffiths DR, Dagher M. Astrocyte-microglia cross-talk in neurodegenerative disease. Nat Rev Neurol. 2023](https://pubmed.ncbi.nlm.nih.gov/36658318/)

References

[Mangold CA, Wold LE et al, Mangold CA, Wold LE. The neuroimmune interface: cytokine networks in brain aging. Ageing Res Rev. 2021;65:101147 (2021)](https://doi.org/10.1016/j.arr.2020.101147)

[Liddelow SA, Barres BA et al, Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957-967 (2017)](https://doi.org/10.1016/j.immuni.2017.06.006)

[Deczkowska A, Weiner A, Amit I et al, Deczkowska A, Weiner A, Amit I. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell. 2020;181(6):1207-1217 (2020)](https://doi.org/10.1016/j.cell.2020.05.014)

[Heneka MT, McManus RM, Latz E et al, Heneka MT, McManus RM, Latz E. NLRP3 inflammasome in spatial and temporal memory. Nat Rev Neurosci. 2019;20(9):521-534 (2019)](https://doi.org/10.1038/s41583-019-0181-x)

[Griffiths DR, Dagher M et al, Griffiths DR, Dagher M. Astrocyte-microglia cross-talk in neurodegenerative disease. Nat Rev Neurol. 2023;19(3):139-151 (2023)](https://doi.org/10.1038/s41582-023-00685-5)

📖 View canonical wiki page →

Related Entities

therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-554e5733c4c6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-section-147-neuroimmune-interface-glial-crosstalk-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

385

Outgoing

405

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

147.1 Rationale for Targeting Neuroimmune Communication

Advanced Neuroimmune Interface and Glial-Neuronal Crosstalk Therapy in CBS/PSP

147.1 Rationale for Targeting Neuroimmune Communication

147.2 Glial-Neuronal Crosstalk Pathways

CX3CL1/CX3CR1 Signaling Axis

CD200/CD200R Pathway

Astrocyte-Neuron Metabolic Coupling

Astrocyte-Microglia Communication

147.3 Therapeutic Targets

TREM2 Modulation

NLRP3 Inflammasome Inhibition

Complement System Modulation

Astrocyte-Targeted Therapies

147.4 Clinical Implementation Protocol

Patient Assessment

Therapeutic Protocol

Phase 1: Baseline Assessment (Weeks 1-4)

Phase 2: Therapeutic Intervention (Weeks 5-16)

Phase 3: Disease-Modifying Approaches (Ongoing)

Monitoring Schedule

147.5 Drug Interactions with Current Regimen

147.6 NET Assessment

147.7 Patient-Specific Recommendations

147.8 Cross-Links

147.9 References

References

💬 Discussion